ライフサイエンスコーパス: end-stage liver disease

1 nt of steatohepatitis, which can progress to end stage liver disease.

2 HCV infection may develop into HCC as an end-stage liver disease.

3 lution of cholestasis and rarely progress to end-stage liver disease.

4 tients required transplantation or died from end-stage liver disease.

5 cirrhosis, liver and kidney transplants, and end-stage liver disease.

6 s a functional renal impairment complicating end-stage liver disease.

7 therapeutic option for a fulminant course or end-stage liver disease.

8 ic for many degenerative diseases, including end-stage liver disease.

9 mains an untapped resource for children with end-stage liver disease.

10 ation is a standard of care for treatment of end-stage liver disease.

11 HCV-coinfected patients to lower the risk of end-stage liver disease.

12 challenges to using these cells in treating end-stage liver disease.

13 virus (HCV) infection is a leading cause of end-stage liver disease.

14 ecurrent cholangitis, biliary cirrhosis, and end-stage liver disease.

15 may sometimes prove fatal for patients with end-stage liver disease.

16 easure of body composition for patients with end-stage liver disease.

17 the allocation policy based on the model for end-stage liver disease.

18 ourage liver fibrogenesis and progression to end-stage liver disease.

19 antation (LTx) is a life-saving treatment of end-stage liver disease.

20 ation at age 50 months for the indication of end-stage liver disease.

21 on is the only alternative for patients with end-stage liver disease.

22 ation can be valuable option for HCV related end-stage liver disease.

23 ibrotic progression and early development of end-stage liver disease.

24 inal, renal, and infectious complications of end-stage liver disease.

25 PSC relative to patients with other forms of end-stage liver disease.

26 term treatment, and frequently progresses to end-stage liver disease.

27 er disease, nonalcoholic steatohepatitis, or end-stage liver disease.

28 in treating kidney failure in patients with end-stage liver disease.

29 gan transplantation (IFOT) for patients with end-stage liver disease.

30 sis does not resolve with FO may progress to end-stage liver disease.

31 Hepatic PP-IX accumulation may lead to end-stage liver disease.

32 py exists to halt disease progression toward end-stage liver disease.

33 iduals are at high risk of developing severe end-stage liver diseases.

34 en species (ROS) are the salient features of end-stage liver diseases.

35 ver cirrhosis, hepatocellular carcinoma, and end-stage liver diseases.

36 new therapeutic strategies for patients with end-stage liver diseases.

37 as LDLT recipients had lower mean model for end-stage liver disease (15.5 vs 20.4) and fewer receive

38 Mean model for end-stage liver disease (28.2 vs. 20.0; P<0.001) and cre

39 Any form of ALD can lead to end-stage liver disease, according to long-term studies

40 discordance at baseline included history of end-stage liver disease (adjusted odds ratio [aOR], 6.52

41 Four variables (Model for End-Stage Liver Disease, alpha-fetoprotein, Milan-Criter

42 seline prognostic scoring systems (Model for End-Stage Liver Disease and age, bilirubin, internationa

43 opin was inversely correlated with Model for End-Stage Liver Disease and Child-Pugh scores and positi

44 H cirrhosis currently are based on model for end-stage liver disease and Child-Pugh-Turcotte scores,

45 dex score, serum level of albumin, model for end-stage liver disease and Child-Turcotte-Pugh scores (

46 The admission model included Model for End-Stage Liver Disease and diabetes (c-statistic = 0.64

47 s a consequence of this complex interaction, end-stage liver disease and hepatocellular carcinoma are

48 people worldwide and is a leading driver of end-stage liver disease and liver cancer.

49 rsibility of renal failure for patients with end-stage liver disease and may be useful in the kidney

50 It is observed in up to 60% of patients with end-stage liver disease and portends a poor prognosis.

51 The end-stage LIVER disease and RALtegravir-Agence Nationale

52 liary atresia (BA), the most common cause of end-stage liver disease and the leading indication for p

53 ednisolone therapy, independent of Model for End-Stage Liver Disease and white blood cell count (OR,

54 onic carriers are at high risk of developing end-stage liver diseases and hepatocellular carcinoma.

55 ate of PLC and the mortality rates of severe end-stage liver diseases and infant fulminant hepatitis

56 were detected and who were free of fibrosis, end-stage liver disease, and chronic hepatitis B at base

57 controlling for age, previous LT, model for end-stage liver disease, and hepatitis C virus.

58 ects of chronic infection include cirrhosis, end-stage liver disease, and hepatocellular carcinoma.

59 reduce the untoward effects of sequelae from end-stage liver disease, and to minimize the requirement

60 The Child Pugh score and Model for End Stage Liver Disease are utilized for surgical risk a

61 90% to 95% of patients with alcohol-related end-stage liver disease are never formally evaluated for

62 tive role for HLA-G after LTX, but show that end-stage liver diseases are associated with HLA-G expre

63 lity following recurrence included model for end-stage liver disease at LT >23, time to recurrence, >

64 Matching was based on: age, sex, model for end-stage liver disease at the time of transplant, type

65 olume, LOS, biliary complications, Model for End-Stage Liver Disease at transplant, and hepatitis C v

66 ates since the introduction of the Model for End-Stage Liver Disease based priority system in Februar

67 Model for End-Stage Liver Disease-based allocation, split, domino,

68 that nongenetic causes of hepcidin loss (eg, end-stage liver disease) can cause acquired forms of hem

69 ermined along with the scores like model for end stage liver disease, child turcotte pugh were record

70 r North American Consortium for the Study of End-Stage Liver Disease cohort.

71 e North American Consortium for the Study of End-Stage Liver Disease consists of 16 tertiary-care hep

72 diabetes (27% vs. 37%; P = 0.02), model for end-stage liver disease era (68% vs. 82%; P = 0.0001), s

73 K transplants by 0.99 years in the Model for End-stage Liver Disease era and 1.71 years in the pre-Mo

74 ysis requirement, hepatitis C, and model for end-stage liver disease era transplantation but was not

75 es published between 2002 and 2016 (model of end-stage liver disease era).

76 Since the model for end-stage liver disease era, there has been a rise in th

77 ease era and 1.71 years in the pre-Model for End-stage Liver Disease era.

78 al brain activity in delirious patients with end stage liver disease (ESLD) is detected by fNIRS.

79 eficiency virus (HIV)-infected patients with end-stage liver disease (ESLD) (substudy 1) and to asses

80 haring SLK transplant policy on outcomes for end-stage liver disease (ESLD) and end-stage renal disea

81 ycocalyx core protein, syndecan-1, occurs in end-stage liver disease (ESLD) and that it increases dur

82 individuals without significant fibrosis or end-stage liver disease (ESLD) at baseline.

83 ss the impact of the program on reduction of end-stage liver disease (ESLD) burden.

84 have compared wait-list mortality risk among end-stage liver disease (ESLD) candidates with high Mode

85 End-stage liver disease (ESLD) caused by hepatitis C vir

86 Patients with end-stage liver disease (ESLD) often have a high symptom

87 Plasma from these and patients with end-stage liver disease (ESLD) suppressed macrophage pro

88 arting point, we analyzed the development of end-stage liver disease (ESLD), hepatocellular carcinoma

89 virus (HCV) is one of the leading causes of end-stage liver disease (ESLD), such as decompensated ci

90 ity of life (QoL) exhibited by patients with end-stage liver disease (ESLD), we studied the associati

91 and C (HCV) viruses are at increased risk of end-stage liver disease (ESLD).

92 months, respectively) who received Model for End Stage Liver Disease exception listing for HCC from 2

93 HPS Model for End-Stage Liver Disease exception patients had lower ove

94 list survival in patients with HPS Model for End-Stage Liver Disease exception points, a pre-transpla

95 thin the Milan criteria for whom a Model for End-Stage Liver Disease exception was approved were retr

96 The Model for End-Stage Liver Disease Excluding international normaliz

97 Since the introduction of the model for end-stage liver disease for the allocation of organs for

98 s of cirrhosis patients with higher Model of End-Stage Liver Disease (>15) showed significantly decre

99 Complications related to end-stage liver disease have significant morbidity and m

100 rable to patients within Milan and model for end-stage liver disease HCC priority.

101 patitis C is the leading cause of cirrhosis, end-stage liver disease, hepatocellular carcinoma, and l

102 ransplantation is an effective treatment for end-stage liver disease; however, demand greatly outweig

103 = 1.895, 95% CI: 1.081-3.323) and model for end stage liver disease (HR = 1.054, 95% CI: 1.020-1.090

104 Biliary atresia is the most common cause of end-stage liver disease in children.

105 n a rapid progression to severe fibrosis and end-stage liver disease in one third of all patients.

106 d with cirrhosis and predicts progression to end-stage liver disease in patients with HBV or HCV infe

107 were found in patients with higher model for end-stage liver disease in the same disease group; and l

108 The final model (United Kingdom End-Stage Liver Disease) included international normaliz

109 There were no differences in Model for End-Stage Liver Disease including serum sodium and Child

110 HCV infection is one of the major causes of end-stage liver disease, including hepatocellular carcin

111 with acute liver failure or complications of end-stage liver disease, including hepatocellular carcin

112 Liver transplantation is the treatment of end-stage liver diseases, including hepatitis C.

113 th longer wait-time, higher rate of model of end-stage liver disease increase, and intermediate 90-da

114 Hepatitis C virus (HCV)-induced end-stage liver disease is the major indication for live

115 ic liver transplantation in the treatment of end-stage liver diseases, its therapeutic utility is sev

116 al fibrillation/flutter, syncope/presyncope, end-stage liver disease, malignancy, and anxiety.

117 Changes in the epidemiology of end-stage liver disease may lead to increased risk of dr

118 (ALT), acute kidney injury (AKI), model for end stage liver disease (MELD) and septic shock are the

119 patients were also dichotomized by Model for End Stage Liver Disease (MELD) score (</=15 vs >15) and

120 Lower pretreatment Model for End Stage Liver Disease (MELD) score was a predictor of

121 The Model for End Stage Liver Disease (MELD) was originally developed

122 King's College criteria (KCC) and Model for End Stage Liver Disease (MELD).

123 er transplantation with laboratory Model for End-Stage Liver Disease (MELD) >/=12 at a single center

124 The Model for End-Stage Liver Disease (MELD) allocation system for liv

125 ysfunction was determined based on model for end-stage liver disease (MELD) and Child-Pugh scores.

126 cs: total mortalities, DSA-average model for end-stage liver disease (MELD) at transplant, DSA-averag

127 Mean model for end-stage liver disease (MELD) at transplantation was 22

128 ndication was defined as DC if the Model for End-Stage Liver Disease (MELD) at WL was >/=15 or hepato

129 nsplant for patients listed with a Model for End-Stage Liver Disease (MELD) between 22 and 27 will do

130 d the impact of this difference on Model for End-Stage Liver Disease (MELD) calculation.

131 transplant candidates, and 242 727 Model of End-Stage Liver Disease (MELD) changes in 2010.

132 gan Sharing to offer a standardized model of end-stage liver disease (MELD) exception for this diseas

133 Current Model for End-Stage Liver Disease (MELD) exception points provided

134 llular carcinoma (HCC) can receive Model for End-Stage Liver Disease (MELD) exception points to incre

135 st priority, centers may apply for model for end-stage liver disease (MELD) exception points to incre

136 nsplantation Network policy grants Model for End-Stage Liver Disease (MELD) exception points to patie

137 The implementation of the model for end-stage liver disease (MELD) in 2002 represented a fun

138 vWF-Ag equals Model for End-Stage Liver Disease (MELD) in mortality prediction (

139 The model for end-stage liver disease (MELD) is based on objective var

140 with a median age of 64 years and Model for End-stage Liver Disease (MELD) MELD of 12.10 (25%) were

141 ellular carcinoma (HCC) additional Model for End-Stage Liver Disease (MELD) points is controversial d

142 Model for End-Stage Liver Disease (MELD) prioritization of liver r

143 or biopsy (HR 3.6; P = 0.001), and Model for End-Stage Liver Disease (MELD) score >/= 20 (HR 3.5; P =

144 re 35, of whom 4,599 (27.9%) had a Model for End-Stage Liver Disease (MELD) score >/=35.

145 at multivariate analysis included Model for End-Stage Liver Disease (MELD) score >10, and absence of

146 own by allocation or by laboratory model for end-stage liver disease (MELD) score (6-14, 15-24, 25-29

147 etes (OR = 2.04, p = 0.01), higher Model for End-Stage Liver Disease (MELD) score (OR = 35.10, p<0.00

148 Baseline Model for End-Stage Liver Disease (MELD) score alone (cut-off 18)

149 This study evaluated the Model for End-Stage Liver Disease (MELD) score and its modified ve

150 ion of liver grafts is based on the Model of End-stage Liver Disease (MELD) score and the use of exce

151 For conditions that the Model for End-Stage Liver Disease (MELD) score does not accurately

152 ; 95% CI, 1.13-4.30; P = .01), and Model for End-Stage Liver Disease (MELD) score greater than 9 (OR,

153 ents for liver transplantation, and the Mayo End-Stage Liver Disease (MELD) score has been used in th

154 Use of the Model for End-Stage Liver Disease (MELD) score has improved the ef

155 estimation of 90-day mortality by Model for End-Stage Liver Disease (MELD) score has improved wait l

156 The Model for End-Stage Liver Disease (MELD) score is predictive of tr

157 Those and patients with a model of end-stage liver disease (MELD) score more than 10 before

158 on in patients with cirrhosis with Model for End-Stage Liver Disease (MELD) score of 12 or less.

159 - 10 years, 63% men) with a median Model for End-Stage Liver Disease (MELD) score of 17 (interquartil

160 and recipients frequently attain a Model for End-Stage Liver Disease (MELD) score of 40 or higher bef

161 The Model for End-Stage Liver Disease (MELD) score predicts higher tra

162 Model for End-Stage Liver Disease (MELD) score transiently worsene

163 Median pre-TIPS model for end-stage liver disease (MELD) score was 15 (7-33).

164 Mean donor age and model for end-stage liver disease (MELD) score were significantly

165 adult patients with cirrhosis and Model for End-Stage Liver Disease (MELD) score within 3 months of

166 livers are primarily allocated by Model for End-Stage Liver Disease (MELD) score within each of the

167 g HCV often improves our patients' model for end-stage liver disease (MELD) score, decreasing costs,

168 Gender, age, Model for End-Stage Liver Disease (MELD) score, diabetes, alcohol

169 mean arterial pressure and higher Model for End-Stage Liver Disease (MELD) score, E-wave transmitral

170 e-LT BNP concentration, adjusted on model of end-stage liver disease (MELD) score, was an independent

171 eatment center, age, CP class, and Model for End-Stage Liver Disease (MELD) score.

172 ered regionally to candidates with Model for End-Stage Liver Disease (MELD) scores >/=35 before being

173 Steadily rising model for end-stage liver disease (MELD) scores at the time of tra

174 However, for HCC patients with model end-stage liver disease (MELD) scores less than 10 and w

175 Patients with Model for End-Stage Liver Disease (MELD) scores of 40 or higher ar

176 splantation with much lower actual Model for End-Stage Liver Disease (MELD) scores than patients with

177 sion patterns of 123 genes and the model for end-stage liver disease (MELD) scores to assign patients

178 isease (ESLD) candidates with high Model for End-Stage Liver Disease (MELD) scores to those listed as

179 Child-Turcotte-Pugh (CTP) and Model for End-stage Liver Disease (MELD) scores were calculated.

180 he effect of therapy on changes in model for end-stage liver disease (MELD) scores were derived from

181 om pre-LT treatment based on their Model for End-Stage Liver Disease (MELD) scores.

182 rtality not well quantified by the Model for End-Stage Liver Disease (MELD) Sodium (MELDNa) score.

183 Refining the Model for End-Stage Liver Disease (MELD) to incorporate reticulocy

184 subgroup analysis by baseline GFR, model for end-stage liver disease (MELD), age, sex, race, and diab

185 ly described models, including the model for end-stage liver disease (MELD), and developed a new MELD

186 day 60; Child-Turcotte-Pugh (CTP), Model for End-Stage Liver Disease (MELD), and Sequential Organ Fai

187 lts were similar to those from the Model for End-Stage Liver Disease (MELD; AUC, peak MELD: 0.77; P <

188 verage donor age and the advent of Model for End-stage Liver Diseases (MELD) score-based allocation c

189 verage donor age and the advent of Model for End-stage Liver Diseases (MELD) score-based allocation c

190 nsplanting higher risk recipients (Model for End-Stage Liver Disease [MELD] score >/=35, inpatient or

191 (56% men; 56 +/- 10 years of age; Model for End-Stage Liver Disease [MELD] score, 20 +/- 8) at 12 ce

192 g the North American Consortium for Study of End-stage Liver Disease (NACSELD) database, data from 18

193 App times were correlated with Model for End-Stage Liver Disease (Offtime: r = 0.57; Ontime: r =

194 storically, cirrhosis from PNALD resulted in end-stage liver disease, often requiring transplantation

195 bstructive cholangiopathy that progresses to end-stage liver disease, often requiring transplantation

196 treat both adult and pediatric patients with end-stage liver disease or acute liver failure.

197 h or very high discordance, including either end-stage liver disease or aspartate transaminase to pla

198 ple in the United States, and often leads to end-stage liver disease or death.

199 with prednisolone, independent of model for end-stage liver disease or Lille score (OR, 2.46; 95% CI

200 k), but the Lille (P < 0.0001) and Model for End-Stage Liver Disease (P < 0.0001) scores were indepen

201 enter study included a cohort of consecutive end-stage liver disease patients with indications for LT

202 d to identify obesity and muscle wasting for end-stage liver disease patients.

203 s 11.6 kg, respectively; P = .87), Model for End-Stage Liver Disease/Pediatric End-Stage Liver Diseas

204 6 mg/dL); P < 0.001], and a higher pediatric end-stage liver disease (PELD) score [22 (14, 25) compar

205 le patients with HCC receive equal model for end-stage liver disease prioritization, despite variable

206 ciated liver fibrosis is a critical step for end-stage liver disease progression.

207 The discharge model included Model for End-Stage Liver Disease, proton pump inhibitor use, and

208 or patients with end-stage renal disease and end-stage liver disease, respectively.

209 ster of differentiation 34+HSCs and Model of End-Stage Liver Disease (rho = -0.582, P < 0.001) and Ch

210 to the severity of liver disease (Model for End-Stage Liver Disease, rho = 0.45, P < 0.001), the deg

211 ted, King's College Criteria (KCC), Model of End Stage Liver Disease score (MELD), and serum sodium b

212 ELD-Na score and the United Kingdom Model of End Stage Liver Disease score (UKELD) were calculated an

213 an age was 51.2 years; 48.0% had a Model for End-Stage Liver Disease score >/=20.

214 Model for End-Stage Liver Disease score >/=25 was associated with

215 lower 12-month graft survival than Model for End-Stage Liver Disease score <15 (P=0.02).

216 Model for End-Stage Liver Disease/Pediatric End-Stage Liver Disease score (19 vs 11, respectively; P

217 05) and to have a higher mean (SD) model for end-stage liver disease score (24 [11] vs. 22 [10], P</=

218 onse rates, LT costs, and baseline Model for End-Stage Liver Disease score (DCC analysis only).

219 liver stiffness (P < 0.001), worse Model for End-Stage Liver Disease score (P < 0.001), more portosys

220 correlated significantly with the Model for End-Stage Liver Disease score (r = -0.39, P < 0.05), fas

221 rage Child score 8.3 (+/-1.3), and Model for End-Stage Liver Disease score 11.7 (+/-3.9).

222 +/- 8 years) were analyzed (median Model for End-Stage Liver Disease score 20).

223 ed after the implementation of the model for end-stage liver disease score and a concomitant increase

224 interval from LRT to LT, and lower model for end-stage liver disease score and maximum tumor diameter

225 r size more than 3 cm (P=0.02) and model for end-stage liver disease score at listing more than 11 (P

226 The median age, body weight, and pediatric end-stage liver disease score at the time of transplant

227 LD had a significantly higher mean Model for End-Stage Liver Disease score at time of waitlist regist

228 Mean Model for End-Stage Liver Disease score at transplant was signific

229 nce of cirrhosis, the dichotomized model for end-stage liver disease score below and above the median

230 cipient age greater than 55 years, Model for End-Stage Liver Disease score greater than 27, history o

231 n were acquisition of CRE post-LT, Model for End-Stage Liver Disease score greater than 32, combined

232 ighting of serum creatinine in the model for end-stage liver disease score has significantly increase

233 ikely to be used in recipients with model of end-stage liver disease score higher than 27 (13.2% vs.

234 , CDI was associated with having a model for end-stage liver disease score of 20 or greater (hazards

235 I was 50.16 +/- 11.7 years with a mean Model End-Stage Liver Disease score of 22.6 +/- 9.8.

236 e excluded candidates with a final Model for End-stage Liver Disease score of less than 15.

237 F, defined as an acute rise in the Model for End-Stage Liver Disease score of more than 5 within 4 we

238 ents with cirrhosis and with worse Model for End-Stage Liver Disease score or diabetes, those taking

239 ren who remained PN-dependent, the Pediatric End-Stage Liver Disease score remained normal throughout

240 Median preoperative model for end-stage liver disease score was 12.

241 s 50.2 +/- 8.5 years, and the mean model for end-stage liver disease score was 12.2 +/- 4.6.

242 The mean Model for End-Stage Liver Disease score was 14.5 +/- 4.

243 Model for End-Stage Liver Disease score was 15 (IQR, 11-21); cold

244 The average Model for End-Stage Liver Disease score was 33.

245 Higher model for end-stage liver disease score was associated with increa

246 The United Kingdom End-Stage Liver Disease score was not associated with ov

247 The baseline Model for End-Stage Liver Disease score was not predictive of long

248 renal function and lower baseline Model for End-Stage Liver Disease score were associated with bette

249 ysis, only the Lille model and the Model for End-Stage Liver Disease score were independently associa

250 used in Donor Risk Index with the model for end-stage liver disease score yields an AUC-ROC of 0.764

251 an age, 56 years; 35% female; mean Model for End-stage Liver Disease score, 10.8; range, 6-40) underw

252 mean Child Pugh, 7 +/- 3; and mean model for end-stage liver disease score, 13 +/- 6) completed the p

253 ss index, hepatitis C virus (HCV), model for end-stage liver disease score, and acute rejection; and

254 al syndrome, dialysis requirement, model for end-stage liver disease score, and alcoholic liver disea

255 and donor length of stay, greater Model for End-stage Liver Disease score, and longer warm and cold

256 ence regarding cold ischemia time, model for end-stage liver disease score, and steatosis.

257 tion, controlling for age, gender, Model for End-Stage Liver Disease score, Child-Pugh score, serum s

258 ting in transplantation at a lower model for end-stage liver disease score, decreased death on waitli

259 tivariate analysis also identified Model for End-Stage Liver Disease score, hypovolemic shock, and ba

260 ated corticosteroid insufficiency, Model for End-Stage Liver Disease score, hypovolemic shock, hepato

261 erative factors (age of recipient, model for end-stage liver disease score, indication for LT, platel

262 adjusting by propensity score and Model for End-Stage Liver Disease score, the NSBB adjusted odds ra

263 ferent age groups who had the same Model for End-Stage Liver Disease score.

264 l group, from baseline (P = .001); Model for End Stage Liver Disease scores were reduced by 40.4% and

265 0.03) compared to those with lower Model of End-Stage Liver Disease scores (</=15).

266 iver transplant recipients with low model of end-stage liver disease scores (<27), without hepatitis

267 patients requiring DC had greater Model for End-stage Liver Disease scores (33 vs 27; P < .001); mor

268 45.1% versus 14.8%), and had lower model for end-stage liver disease scores (median 9 versus 10) (all

269 fter LT was associated with higher model for end-stage liver disease scores and receiving a LT from a

270 plantation network so that patient model for end-stage liver disease scores at transplant is more uni

271 Renal impairment and high model of end-stage liver disease scores before liver transplantat

272 Pediatric End-Stage Liver Disease scores decreased from 16 +/- 4.6

273 maintained at 6 months; Child and Model for End-Stage Liver Disease scores did not change.

274 Child-Turcotte-Pugh and model for end-stage liver disease scores improved significantly fr

275 a high-quality liver when they had Model for End-stage Liver Disease scores of 15 or greater (P = .00

276 Mean model for end-stage liver disease scores were 21.64 in the HCV gro

277 needed to calculate Child-Pugh and Model for End-Stage Liver Disease scores were recorded.

278 ysfunction (Child-Turcotte-Pugh or Model for End-Stage Liver Disease scores).

279 as well as Child-Turcotte-Pugh and model for end-stage liver disease scores, in patients with cirrhos

280 had significantly lower laboratory model for end-stage liver disease scores, pretransplant alpha feto

281 orrelated with both Child-Pugh and Model for End-Stage Liver Disease scores.

282 morbidities unaccounted for by the model for end-stage liver disease scoring system and may benefit f

283 se and cost-effective step for patients with end-stage liver disease seeking alternative ways from th

284 Since the adoption of the Model for End-Stage Liver Disease, simultaneous liver/kidney trans

285 Cancer stage D ( P < .001), higher Model for End-Stage Liver Disease Sodium scores ( P < .001), highe

286 Adjusting for sex, age, Model for End-Stage Liver Disease, sodium, and Charlson index, the

287 ortality was homogenous across all Model for End-Stage Liver Disease spectrums.

288 lications to the development of fibrosis and end-stage liver diseases, such as cirrhosis and hepatoce

289 ollowing the implementation of the model for end-stage liver disease system for liver transplantation

290 virus (HCV) infection is a leading cause of end-stage liver disease that necessitates liver transpla

291 myopathy, 10 normal ejection fraction, and 9 end-stage liver disease) underwent simultaneous echocard

292 either potential living donors or Model for End-Stage Liver Disease upgrade for hepatocellular carci

293 usting for significant covariates (Model for End-Stage Liver Disease, vasopressor use).

294 riate analysis recipient age, sex, model for end stage liver disease, viral etiology had no bearing o

295 ude neonatal onset with rapid progression to end-stage liver disease, vitamin K-independent coagulopa

296 roportion of patients with clinical signs of end-stage liver disease was observed in the non-SVR grou

297 shock, hepatic encephalopathy and model for end stage liver disease were significantly different amo

298 full enteral feeding developed cirrhosis and end-stage liver disease, which require liver transplanta

299 titis C virus (HCV) is an important cause of end stage liver disease worldwide.

300 HCV infection is one of the major causes of end-stage liver disease worldwide.